e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Immune mechanisms in the human lung
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment
Joanna Hermanowicz-Salamon (Warsaw, Poland), Joanna Hermanowicz-Salamon, Patrycja Nejman-Gryz, Renata Rubinsztajn, Magdalena Paplinska-Goryca, Ryszarda Chazan
Source:
International Congress 2015 – Immune mechanisms in the human lung
Session:
Immune mechanisms in the human lung
Session type:
Thematic Poster Session
Number:
4041
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Joanna Hermanowicz-Salamon (Warsaw, Poland), Joanna Hermanowicz-Salamon, Patrycja Nejman-Gryz, Renata Rubinsztajn, Magdalena Paplinska-Goryca, Ryszarda Chazan. Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment. Eur Respir J 2015; 46: Suppl. 59, 4041
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015
Patients with allergic and eosinophilic asthma in the German severe asthma registry
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015
Combined therapy of asthma and allergic rhinitis
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta
Source: International Congress 2016 – Asthma management
Year: 2016
Clinical effectiveness of anti-IgE therapy in allergic severe asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma
Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Year: 2015
Subcutaneous allergen specific immunotherapy and immunological response in patients with bronchial asthma and allergic rhinitis in India
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
First clinical trial of a new IgE-adsorber in allergic asthma
Source: International Congress 2015 – Novel mechanisms and treatments in allergy and asthma
Year: 2015
Total and free IgE in evolution of severe asthma after omalizumab treatment
Source: International Congress 2016 – Asthma management
Year: 2016
Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma
Source: Annual Congress 2013 –Studies of asthma in man
Year: 2013
Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma whether due to seasonal allergens or to perennial allergens
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015
IL-17A in severe asthma, severe asthma with fungal sensitisation and ABPA
Source: International Congress 2015 – Phenotyping asthma with biomarkers
Year: 2015
Airway hyperresponsiveness in patients treated with omalizumab
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015
Free serum IL-18 levels and responsiveness to omalizumab in patients with severe asthma
Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding
Year: 2016
Allergic rhinitis does it have an impact on controller asthma therapy choice
Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management
Year: 2014
Study of some inflammatory markers in children with moderate persistent bronchial asthma before and after therapy with inhaled corticosteroids
Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules
Year: 2013
The usefulness of FeNO and the mannitol test in detecting airway eosinophilia in asthma patients with uncontrolled symptoms
Source: International Congress 2014 – Biomarkers of asthma control
Year: 2014
Clinical experience with montelukast plus ICS vs. only ICS in non-asthmatic eosinophilic bronchitis (NAEB) in Indian patients
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016
Long-term using of omalizumab in children with atopic severe persistent non-controlled asthma
Source: Annual Congress 2013 –Uncontrolled and severe asthma in children
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept